TAE648
Based on 1 Customer Validation
TAE648 is a target protein ligand of PROTAC SK-3-91 (HY-137341) (Ligand for Target Protein for PROTAC). TAE648 can be used for synthesis PROTAC. TAE648 decreases monolayer-cultured SKOV3ip1 cell viability.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.50%
- No. CAS: 2769753-10-6
- Fòrmula: C23H27ClN6O2S
- Peso molecular:487.02
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Ver todos los productos específicos de isoformas Aurora Kinase
More
Actividad biológica
|
YTHDF2 |
TEC |
Chemical Information
-
No. CAS 2769753-10-6
-
Appearance Solid
-
Peso molecular 487.02
-
Fòrmula C23H27ClN6O2S
-
Color White to off-white
-
SMILES
ClC(C=N1)=C(NC2=C(S(C(C)C)(=O)=O)C=CC=C2)N=C1NC(C=C3)=CC=C3N4CCNCC4
-
Synonyms
TL13-87
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 100 mg/mL (205.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Donovan KA, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020;183(6):1714-1731.e10. [Content Brief]
[2]. Cha HJ, et al. Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells. Int J Oncol. 2017 Apr;50(4):1279-1288. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0533 mL | 10.2665 mL | 20.5330 mL | 51.3326 mL |
| 5 mM | 0.4107 mL | 2.0533 mL | 4.1066 mL | 10.2665 mL | |
| 10 mM | 0.2053 mL | 1.0267 mL | 2.0533 mL | 5.1333 mL | |
| 15 mM | 0.1369 mL | 0.6844 mL | 1.3689 mL | 3.4222 mL | |
| 20 mM | 0.1027 mL | 0.5133 mL | 1.0267 mL | 2.5666 mL | |
| 25 mM | 0.0821 mL | 0.4107 mL | 0.8213 mL | 2.0533 mL | |
| 30 mM | 0.0684 mL | 0.3422 mL | 0.6844 mL | 1.7111 mL | |
| 40 mM | 0.0513 mL | 0.2567 mL | 0.5133 mL | 1.2833 mL | |
| 50 mM | 0.0411 mL | 0.2053 mL | 0.4107 mL | 1.0267 mL | |
| 60 mM | 0.0342 mL | 0.1711 mL | 0.3422 mL | 0.8555 mL | |
| 80 mM | 0.0257 mL | 0.1283 mL | 0.2567 mL | 0.6417 mL | |
| 100 mM | 0.0205 mL | 0.1027 mL | 0.2053 mL | 0.5133 mL |